Equity Overview
Price & Market Data
Price: $5.05
Daily Change: -$0.18 / 3.56%
Daily Range: $5.05 - $5.37
Market Cap: $8,142,867
Daily Volume: 17,234
Performance Metrics
1 Week: -20.16%
1 Month: 66.99%
3 Months: -4.86%
6 Months: -48.28%
1 Year: -70.57%
YTD: 173.3%
Company Details
Employees: 20
Sector: Health technology
Industry: Biotechnology
Country:
Details
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.